PMID- 25995644
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150521
LR  - 20220321
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 8
DP  - 2015
TI  - SIRT1 expression is associated with poor prognosis of lung adenocarcinoma.
PG  - 977-84
LID - 10.2147/OTT.S82378 [doi]
AB  - Several studies have reported that the overexpression of Sirtuin 1 (SIRT1) was 
      associated with poor prognosis in various human cancers. However, little is known 
      regarding the prognostic value of SIRT1 in lung adenocarcinoma. Therefore, the 
      aim of this study is to evaluate the role of SIRT1 in the prognosis of lung 
      adenocarcinoma patients. Using a tissue microarray, we detected SIRT1 expression 
      by immunohistochemistry in lung adenocarcinoma tissue, as well as in 
      corresponding noncancerous tissues (NCTs). A high expression level of SIRT1 was 
      observed in 74.7% (56/75) of patients with lung adenocarcinoma and 6.7% (5/75) of 
      NCTs (P<0.001). SIRT1 expression was significantly associated with high 
      pathological stage. Importantly, we found that SIRT1 expression was associated 
      with worse overall survival in these lung adenocarcinoma patients (67.0 months vs 
      104.5 months; P=0.005). In addition, anaplastic lymphoma kinase, epidermal growth 
      factor receptor, vascular endothelial growth factor (VEGF), and Survivin 
      expression were evaluated by fluorescent in situ hybridization or 
      immunohistochemistry, respectively. We found that VEGF and Survivin were both 
      highly expressed in the lung adenocarcinoma tissues, as compared to NCTs. 
      Moreover, the SIRT1 and VEGF expression statuses were significantly positively 
      correlated (r=0.238, P=0.039), while SIRT1 and Survivin expression status were 
      not significantly correlated (r=0.220, P=0.058). Correlation analysis showed a 
      positive correlation between VEGF and Survivin expression (r=0.436, P<0.001). 
      However, we found that VEGF and Survivin expression were not associated with the 
      prognosis of lung adenocarcinoma patients (P=0.334; P=0.433, respectively). Taken 
      together, our findings suggest that SIRT1 plays a role in the progression of lung 
      adenocarcinoma and may be a significant prognostic indicator for lung 
      adenocarcinoma patients.
FAU - Li, Chong
AU  - Li C
AD  - Department of Tumor Biological Treatment, the Third Affiliated Hospital, Soochow 
      University, Changzhou, People's Republic of China ; Cancer Immunotherapy 
      Engineering Research Center of Jiangsu Province, Changzhou, People's Republic of 
      China.
FAU - Wang, Lingling
AU  - Wang L
AD  - Department of Medical Education, Jinling Hospital, Medical School of Nanjing 
      University, Nanjing, People's Republic of China.
FAU - Zheng, Liang
AU  - Zheng L
AD  - Department of Thoracic Surgery, the Third Affiliated Hospital, Soochow 
      University, Changzhou, Jiangsu, People's Republic of China.
FAU - Zhan, Xianghong
AU  - Zhan X
AD  - Department of Thoracic Surgery, the Third Affiliated Hospital, Soochow 
      University, Changzhou, Jiangsu, People's Republic of China.
FAU - Xu, Bin
AU  - Xu B
AD  - Department of Tumor Biological Treatment, the Third Affiliated Hospital, Soochow 
      University, Changzhou, People's Republic of China ; Cancer Immunotherapy 
      Engineering Research Center of Jiangsu Province, Changzhou, People's Republic of 
      China.
FAU - Jiang, Jingting
AU  - Jiang J
AD  - Department of Tumor Biological Treatment, the Third Affiliated Hospital, Soochow 
      University, Changzhou, People's Republic of China ; Cancer Immunotherapy 
      Engineering Research Center of Jiangsu Province, Changzhou, People's Republic of 
      China.
FAU - Wu, Changping
AU  - Wu C
AD  - Department of Tumor Biological Treatment, the Third Affiliated Hospital, Soochow 
      University, Changzhou, People's Republic of China ; Cancer Immunotherapy 
      Engineering Research Center of Jiangsu Province, Changzhou, People's Republic of 
      China.
LA  - eng
PT  - Journal Article
DEP - 20150430
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC4425340
OTO - NOTNLM
OT  - SIRT1
OT  - Survivin
OT  - VEGF
OT  - lung adenocarcinoma
OT  - prognosis
EDAT- 2015/05/23 06:00
MHDA- 2015/05/23 06:01
PMCR- 2015/04/30
CRDT- 2015/05/22 06:00
PHST- 2015/05/22 06:00 [entrez]
PHST- 2015/05/23 06:00 [pubmed]
PHST- 2015/05/23 06:01 [medline]
PHST- 2015/04/30 00:00 [pmc-release]
AID - ott-8-977 [pii]
AID - 10.2147/OTT.S82378 [doi]
PST - epublish
SO  - Onco Targets Ther. 2015 Apr 30;8:977-84. doi: 10.2147/OTT.S82378. eCollection 
      2015.